415 related articles for article (PubMed ID: 21723881)
1. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
2. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
3. Sequence determinants of subtype-specific actions of KCNQ channel openers.
Wang AW; Yang R; Kurata HT
J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
5. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
[TBL] [Abstract][Full Text] [Related]
6. Activation of KCNQ2/3 potassium channels by novel pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives.
Jia C; Qi J; Zhang F; Mi Y; Zhang X; Chen X; Liu L; Du X; Zhang H
Pharmacology; 2011; 87(5-6):297-310. PubMed ID: 21577044
[TBL] [Abstract][Full Text] [Related]
7. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
Tatulian L; Brown DA
J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
[TBL] [Abstract][Full Text] [Related]
8. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.
Miceli F; Soldovieri MV; Martire M; Taglialatela M
Curr Opin Pharmacol; 2008 Feb; 8(1):65-74. PubMed ID: 18061539
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of M-type KCNQ (Kv7) K+ channel assembly.
Schwake M; Athanasiadu D; Beimgraben C; Blanz J; Beck C; Jentsch TJ; Saftig P; Friedrich T
J Neurosci; 2006 Apr; 26(14):3757-66. PubMed ID: 16597729
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel openers using QPatch HT.
Zhang XF; Zhang D; Surowy CS; Yao B; Jarvis MF; McGaraughty S; Neelands TR
Assay Drug Dev Technol; 2013 Feb; 11(1):17-24. PubMed ID: 23002961
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Zhou P; Yu H; Gu M; Nan FJ; Gao Z; Li M
Proc Natl Acad Sci U S A; 2013 May; 110(21):8726-31. PubMed ID: 23650395
[TBL] [Abstract][Full Text] [Related]
12. Functional and behavioral signatures of Kv7 activator drug subtypes.
Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
[TBL] [Abstract][Full Text] [Related]
13. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.
Xiong Q; Sun H; Zhang Y; Nan F; Li M
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3128-33. PubMed ID: 18272489
[TBL] [Abstract][Full Text] [Related]
15. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
16. Pore- and voltage sensor-targeted KCNQ openers have distinct state-dependent actions.
Wang CK; Lamothe SM; Wang AW; Yang RY; Kurata HT
J Gen Physiol; 2018 Dec; 150(12):1722-1734. PubMed ID: 30373787
[TBL] [Abstract][Full Text] [Related]
17. Drosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.
Cavaliere S; Hodge JJ
PLoS One; 2011; 6(9):e23898. PubMed ID: 21915266
[TBL] [Abstract][Full Text] [Related]
18. Recent developments on KCNQ potassium channel openers.
Wua YJ; Dworetzky SI
Curr Med Chem; 2005; 12(4):453-60. PubMed ID: 15720253
[TBL] [Abstract][Full Text] [Related]
19. The Amyloid Precursor Protein C99 Fragment Modulates Voltage-Gated Potassium Channels.
Manville RW; Abbott GW
Cell Physiol Biochem; 2021 Jul; 55(S3):157-170. PubMed ID: 34318654
[TBL] [Abstract][Full Text] [Related]
20. Heteromeric Assembly of Truncated Neuronal Kv7 Channels: Implications for Neurologic Disease and Pharmacotherapy.
Li J; Maghera J; Lamothe SM; Marco EJ; Kurata HT
Mol Pharmacol; 2020 Sep; 98(3):192-202. PubMed ID: 32580997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
